GNPTG-Mucolipidosis

Mendelian MONDO:0009652 Pathograph 10 Show in embeddings browser Lysosomal Storage Disorder

GNPTG-mucolipidosis (mucolipidosis III gamma) is the attenuated form of GlcNAc-1-phosphotransferase deficiency, caused by biallelic variants in GNPTG encoding the gamma subunit of the enzyme that initiates mannose-6-phosphate (M6P) tagging of soluble lysosomal hydrolases. Loss of M6P tagging missorts and hypersecretes lysosomal enzymes, leaving lysosomes functionally deficient and causing slowly progressive substrate accumulation. It is a slowly progressive disorder mainly affecting skeletal, joint, and connective tissues, generally milder than GNPTAB-related mucolipidosis, with survival into adulthood and relatively preserved cognition.

Ask OpenScientist

Ask a research question about GNPTG-Mucolipidosis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Definitions
1
Inheritance
2
Pathophys.
9
Phenotypes
1
Gaps
10
Pathograph
1
Genes
4
Medical Actions
1
Differentials
2
Models
1
References
1
Deep Research
🏷

Classifications

ISDS Skeletal Nosology
lysosomal storage with skeletal involvement
🔗

Mappings

MONDO
MONDO:0009652 GNPTG-mucolipidosis
skos:exactMatch MONDO
Primary MONDO disease identifier for this mucolipidosis III gamma entry.
📘

Definitions

1
Clinical case definition of mucolipidosis III gamma
Mucolipidosis III gamma is the attenuated GlcNAc-1-phosphotransferase deficiency caused by biallelic GNPTG variants, defined by a mannose-6-phosphate targeting defect with slowly progressive skeletal, joint, and connective-tissue disease.
CASE_DEFINITION Disease-level case definition for GNPTG-mucolipidosis (ML III gamma).
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"Mucolipidosis III gamma (ML IIIγ) is a slowly progressive inborn error of metabolism mainly affecting skeletal, joint, and connective tissues."
Anchors the case definition in the GNPTG-related connective-tissue mucolipidosis.
👪

Inheritance

1
Autosomal recessive HP:0000007
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:34172897 SUPPORT Human Clinical
"rare autosomal recessive lysosomal storage disorders"
Mucolipidosis III gamma is autosomal recessive.
?

Discussions and Knowledge Gaps

1
Do Gnptg-null mice have a cartilage phenotype?
CONTROVERSY OPEN gnptg_mouse_cartilage_conflict
Attached to
animal_models#Gnptg-null mouse, Lexicon line (Gnptg tm1Lex) animal_models#Gnptg-null mouse, Hamburg line (Gnptg ko) pathophysiology#Lysosomal Substrate Accumulation in Connective Tissue
Two reports of gamma-subunit null mice reach opposite conclusions. The 2009 comparative pathology study reports that the gamma-null mice "lacked cartilage defects", and uses that absence, with the absent retinal degeneration, to argue the line is milder than the alpha/beta knockout. The 2020 study reports intracellular chondroitin sulfate accumulation in Gnptg knockout chondrocytes, impaired chondrocyte differentiation, and altered cartilage extracellular matrix microstructure. Four candidate explanations are on the table and none has been tested against the others. First, the two papers do not use the same mouse: the 2020 Animals section attributes its line to Kollmann and Di Lorenzo, a different provenance from the Lexicon allele carrying the 2009 result, so line and background differences are a live explanation rather than a formality. Second, depth of assay differs - the earlier study read histology and gross phenotype, the later one measured matrix ultrastructure, substrate content and chondrocyte differentiation, so a defect invisible at one resolution may be plain at another. Third, the 2009 authors offer their own mechanistic account, attributing the absent chondrocyte and retinal lesions to residual beta-glucuronidase activity, which is a residual-activity explanation of the same kind that organises the rest of this entry. Fourth, the animals may not be of comparable age: the 2020 work reports on aged joints and tendon, while the 2009 abstract does not state its timepoints. Recorded so the entry does not silently adopt one report over the other.
Proposed experiments
Both gamma-null lines assayed side by side at matched ages with the deeper cartilage endpoints
gnptg_cartilage_head_to_head_matched_age
Take the Lexicon line and the Hamburg line into one experiment and apply the 2020 endpoints to both at the same ages: chondrocyte chondroitin sulfate content, chondrocyte differentiation markers, and cartilage extracellular matrix ultrastructure, alongside the histology and gross skeletal assessment the 2009 study used. This is the one design that separates the first two candidate explanations from each other, because a line difference and a depth-of-assay difference make opposite predictions once line and assay are varied independently.
Would support
pathophysiology#Lysosomal Substrate Accumulation in Connective Tissue
Would refute
pathophysiology#Lysosomal Substrate Accumulation in Connective Tissue
Supporting outcome
  • Both lines show chondroitin sulfate accumulation and matrix change at the deeper endpoints while both remain unremarkable on histology alone, which would make depth of assay the explanation and the cartilage phenotype a property of gamma-subunit loss rather than of one line.
Refuting outcome
  • The Hamburg line reproduces the 2020 findings and the Lexicon line remains unaffected at the same endpoints and ages, which would make the line difference the explanation and leave the cartilage phenotype unestablished for gamma-subunit loss in general.
Residual beta-glucuronidase activity in cartilage of both gamma-null lines
gnptg_residual_beta_glucuronidase_in_cartilage
Measure beta-glucuronidase activity in chondrocytes and cartilage of both lines against wild-type and against the alpha/beta knockout, to test the 2009 authors' own account of the absence they report. The claim is currently an untested hypothesis offered in a discussion sentence, and it is the candidate explanation most directly checkable, since the residual activity it invokes is a quantity rather than a difference in husbandry or method.
Supporting outcome
  • Residual beta-glucuronidase activity in cartilage tracks inversely with cartilage involvement across the lines, supporting a graded-activity threshold above which the tissue is spared.
Refuting outcome
  • Residual beta-glucuronidase activity is comparable in the two lines despite their differing cartilage findings, which would eliminate the 2009 authors' account and leave line provenance, assay depth or animal age carrying the discrepancy.
Show evidence (3 references)
PMID:19261645 REFUTE Model Organism
"In contrast to mice deficient in the alpha/beta subunits, the mice lacking the gamma subunits were of normal size, lacked cartilage defects, and did not develop retinal degeneration."
The report that the Lexicon line has no cartilage defect.
PMID:19261645 REFUTE Model Organism
"The absence of retinal and chondrocyte lesions in Gnptg(-/-) mice might be attributed to residual beta-glucuronidase activity."
The sentence presupposes the absent chondrocyte lesions in order to explain them, so it asserts the absence as well as accounting for it. Its distinctive content is that account - residual beta-glucuronidase activity - which the rationale carries as one of the four candidate explanations.
PMID:33023972 SUPPORT Model Organism
"missorting of a number of lysosomal enzymes is associated with intracellular accumulation of chondroitin sulfate in Gnptgko chondrocytes and their impaired differentiation, as well as with altered microstructure of the cartilage extracellular matrix (ECM)"
The report that a gamma-null line does have a cartilage phenotype.
⚙

Pathophysiology

2
GlcNAc-1-Phosphotransferase Gamma-Subunit Deficiency and M6P Targeting Failure
Biallelic GNPTG variants impair the gamma subunit of GlcNAc-1-phosphotransferase, reducing mannose-6-phosphate tagging of soluble acid hydrolases. Untagged enzymes are missorted and hypersecreted into plasma rather than delivered to the lysosome, leaving the lysosome functionally deficient in multiple hydrolases.
fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
GNPTG hgnc:23026 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GNPTG (hgnc:23026). hgnc:23026 is a gene from the HUGO Gene Nomenclature Committee.
protein targeting to lysosome GO:0006622 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased protein targeting to lysosome (GO:0006622). GO:0006622 is a biological process from the Gene Ontology.
Animal models
Gnptg-null mouse, Lexicon line (Gnptg tm1Lex) Mouse recapitulates Germline loss of the orthologous subunit, with the partial rather than complete tagging defect that distinguishes gamma-subunit disease from alpha/beta-subunit disease.
Downstream
Lysosomal Substrate Accumulation in Connective Tissue Functional lysosomal hydrolase deficiency leads to substrate accumulation.
Show evidence (2 references)
PMID:34172897 SUPPORT Human Clinical
"Mucolipidosis (ML) II, MLIII alpha/beta, and MLIII gamma are rare autosomal recessive lysosomal storage disorders."
Mucolipidosis III gamma is a lysosomal storage disorder in the GlcNAc-1-phosphotransferase spectrum.
PMID:30882951 SUPPORT Human Clinical
"MLIII alpha/beta and MLIII gamma are attenuated forms of the disease"
GNPTG-related ML III gamma is an attenuated form within the GNPTAB/GNPTG disease spectrum.
Lysosomal Substrate Accumulation in Connective Tissue
Functional deficiency of multiple lysosomal hydrolases leads to slowly progressive accumulation of undegraded substrates, predominantly affecting skeletal, joint, and connective tissues.
fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
lysosomal transport GO:0007041 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal lysosomal transport (GO:0007041). GO:0007041 is a biological process from the Gene Ontology.
lysosome GO:0005764 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves lysosome (GO:0005764). GO:0005764 is a cellular component from the Gene Ontology.
Animal models
Gnptg-null mouse, Lexicon line (Gnptg tm1Lex) Mouse partially recapitulates Storage develops, but not in the tissue compartment that defines the human disease.
Gnptg-null mouse, Hamburg line (Gnptg ko) Mouse partially recapitulates Substrate accumulates inside chondrocytes and the cartilage matrix is altered, which is the connective-tissue storage this node names.
Downstream
Skeletal dysplasia Connective-tissue and skeletal lysosomal storage produces progressive skeletal dysplasia.
Limitation of joint mobility Joint and connective-tissue involvement restricts mobility.
Chronic pain Progressive skeletal and joint disease produces chronic pain and functional impairment.
Cardiac valve disease Connective-tissue storage affects cardiac valves, producing valvular thickening and insufficiency.
Carpal tunnel syndrome Connective-tissue thickening can compress the median nerve in the carpal tunnel.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"Mucolipidosis III gamma (ML IIIγ) is a slowly progressive inborn error of metabolism mainly affecting skeletal, joint, and connective tissues."
Substrate accumulation predominantly affects skeletal, joint, and connective tissues.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for GNPTG-Mucolipidosis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Cardiovascular 2
Cardiac valve disease Mitral regurgitation HP:0001653 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mitral regurgitation (HP:0001653). HP:0001653 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"thickening and insufficiency of the mitral and aortic valves"
Cardiac valve thickening and insufficiency occur in ML III gamma.
Aortic valve insufficiency Aortic regurgitation HP:0001659 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aortic regurgitation (HP:0001659). HP:0001659 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"thickening and insufficiency of the mitral and aortic valves"
GeneReviews reports thickening and insufficiency of the aortic (as well as mitral) valve in ML III gamma.
Musculoskeletal 2
Skeletal dysplasia HP:0002652 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Skeletal dysplasia (HP:0002652). HP:0002652 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"Mucolipidosis III gamma (ML IIIγ) is a slowly progressive inborn error of metabolism mainly affecting skeletal, joint, and connective tissues."
Skeletal involvement is a major feature.
Limitation of joint mobility HP:0001376 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Limitation of joint mobility (HP:0001376). HP:0001376 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"mainly affecting skeletal, joint, and connective tissues"
Joint involvement with progressive restriction is characteristic.
Nervous System 3
Carpal tunnel syndrome Constrictive median neuropathy HP:0012185 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Constrictive median neuropathy (HP:0012185). HP:0012185 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"carpal tunnel and, rarely, tarsal tunnel syndrome may require surgica"
Carpal tunnel syndrome is a recognized complication requiring surgical management.
Motor delay HP:0001270 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Motor delay (HP:0001270). HP:0001270 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"Motor milestones can be affected due to joint"
GeneReviews attributes affected motor milestones to joint disease in ML III gamma.
Cognitive impairment VERY_RARE HP:0100543 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cognitive impairment (HP:0100543). HP:0100543 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"A few (probably <5%) affected individuals display mild cognitive"
GeneReviews reports mild cognitive impairment in a minority (<5%) of individuals with ML III gamma.
Respiratory 1
Restrictive lung disease Restrictive ventilatory defect HP:0002091 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Restrictive ventilatory defect (HP:0002091). HP:0002091 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"restrictive lung disease from thoracic"
GeneReviews reports restrictive lung disease from thoracic involvement as a cardiorespiratory complication of ML III gamma.
Constitutional 1
Chronic pain HP:0012532 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chronic pain (HP:0012532). HP:0012532 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"severe functional impairment and significant morbidity from chronic pain"
Chronic pain is a major source of morbidity in ML III gamma.
🧬

Genetic Associations

1
GNPTG (Biallelic GNPTG variants impairing the GlcNAc-1-phosphotransferase gamma subunit)
Gene: GNPTG hgnc:23026 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GNPTG (hgnc:23026). hgnc:23026 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (1 reference)
PMID:30882951 SUPPORT Human Clinical
"GNPTAB and GNPTG encode the α/β-precursor and the γ-subunit of N-acetylglucosamine (GlcNAc)-1-phosphotransferase, respectively"
GNPTG encodes the gamma subunit of GlcNAc-1-phosphotransferase; its biallelic loss causes ML III gamma.
💊

Medical Actions

4
Supportive Care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
No disease-modifying therapy is established; management is supportive, with orthopedic and physiotherapeutic care for the musculoskeletal disease.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"Braces (especially of the hands) at night may improve daily functions"
Supportive measures such as night braces improve daily function in ML III gamma.
Bisphosphonate Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Bisphosphonate treatment is used in individuals with significant skeletal disease and bone pain.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"Bisphosphonate treatment in individuals with significant skeletal dis"
Bisphosphonates are used for the significant skeletal disease and bone pain.
Joint Replacement Surgery
Action: joint replacementNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is joint replacement (NCIT:C131579). NCIT:C131579 is a clinical intervention from the NCI Thesaurus. Ontology label: Joint Replacement NCIT:C131579
Joint replacement (especially hip and knee) relieves pain and improves function in older adolescents and adults.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"joint replacement has been successful in relieving hip pain and knee"
Joint replacement successfully relieves hip and knee pain in ML III gamma.
Pain Management
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
As skeletal disease intensifies, management focuses on pain relief, including for chronic pain.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"management focuses on pain relief"
Pain relief is a central component of ML III gamma management.
🔬

Diagnosis

2
Plasma lysosomal enzyme activity and GNPTG sequencing
Markedly elevated activities of multiple lysosomal enzymes in plasma/serum (from hypersecretion) with reduced intracellular activity suggests a mannose-6-phosphate targeting defect; diagnosis is confirmed by GNPTG sequencing.
clinical laboratory procedure NCIT:C25294 NCI Thesaurus (NCIT)
Markers: Elevated plasma lysosomal enzyme activities with reduced intracellular activity.
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"The diagnosis of ML IIIγ is established in a proband with suggestive clinical and radiographic findings and biallelic pathogenic variants in GNPTG identified by molecular genetic testing"
Diagnosis combines suggestive clinical/radiographic findings with biallelic GNPTG variants on molecular testing.
GNPTG molecular genetic testing
Confirmatory biallelic GNPTG sequencing.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:20301784 SUPPORT Human Clinical
"biallelic pathogenic variants in GNPTG identified by molecular genetic testing"
Biallelic GNPTG variants on molecular genetic testing provide diagnostic confirmation.
🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from GNPTG-Mucolipidosis:

Mucolipidosis type II MONDO:0009650
Overlapping Features The severe end of the GlcNAc-1-phosphotransferase spectrum (GNPTAB), with infantile onset and early death.
Distinguishing Features
  • GNPTAB defects with severe infantile-onset disease and death in early childhood, versus the attenuated GNPTG form.
Show evidence (1 reference)
PMID:34172897 SUPPORT Human Clinical
"Mucolipidosis (ML) II, MLIII alpha/beta, and MLIII gamma are rare autosomal recessive lysosomal storage disorders."
ML II and ML III gamma are distinct severities within the same phosphotransferase spectrum.
🐁

Animal Models

2
Gnptg-null mouse, Lexicon line (Gnptg tm1Lex)
Knockout of the GlcNAc-1-phosphotransferase gamma subunit, studied alongside the alpha/beta-subunit knockout that models mucolipidosis II. The pairing is what makes this model informative: losing the gamma subunit causes only a partial loss of mannose-6-phosphate tagging, where losing alpha/beta abolishes it, and the severity of storage disease in the two lines tracks the residual enzyme activity. That graded relationship is the mouse counterpart of the milder human ML III gamma against ML II.
Species
Mouse
Genotype
Gnptg<tm1Lex>/Gnptg<tm1Lex>
Alleles
Gnptg<tm1Lex>
Genes
GNPTG hgnc:23026 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns GNPTG (hgnc:23026). hgnc:23026 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:19261645
Pathograph links
GlcNAc-1-Phosphotransferase Gamma-Subunit Deficiency and M6P Targeting Failure recapitulates fidelity: high observes: organism Germline loss of the orthologous subunit, with the partial rather than complete tagging defect that distinguishes gamma-subunit disease from alpha/beta-subunit disease.
Limitations: A complete gamma-subunit null models the severe end of the GNPTG allelic spectrum, whereas most human ML III gamma alleles retain some subunit function.
Readouts
Mannose 6-phosphorylation of acid hydrolases
Direction: DECREASED
Interpretation: Partial, not abolished. The same study measured complete loss in the alpha/beta knockout, so this readout is the quantitative difference between ML III gamma and ML II rather than a shared defect.
Show evidence (1 reference)
PMID:17652091 SUPPORT Model Organism
"disruption of the alpha/beta gene completely abolishes phosphorylation of high mannose oligosaccharides on acid hydrolases whereas knock-out of the gamma gene results in only a partial loss of phosphorylation"
Measures the residual phosphotransferase activity in this genotype against the alpha/beta null assayed in the same study.
Serum lysosomal enzyme levels
Direction: INCREASED
Interpretation: Enzyme amount rising in the wrong compartment because the tagging that routes hydrolases to the lysosome is impaired. It must not be read as preserved lysosomal function.
Show evidence (1 reference)
PMID:19261645 SUPPORT Model Organism
"We found that both lines of mutant mice had elevated levels of serum lysosomal enzymes and cytoplasmic alterations in secretory cells of several exocrine glands; however, lesions in gamma-subunit deficient (Gnptg(-/-)) mice were milder and more restricted in distribution than in..."
Reports the raised circulating hydrolases and the milder, more restricted lesion distribution relative to the alpha/beta null.
Show evidence (1 reference)
PMID:19261645 SUPPORT Model Organism
"The milder disease in the gamma-subunit deficient mice correlated with residual synthesis of the mannose 6-phosphate recognition marker."
Ties the milder phenotype directly to residual M6P tagging, which is the mechanism this node names.
Lysosomal Substrate Accumulation in Connective Tissue partially recapitulates fidelity: low observes: organism Storage develops, but not in the tissue compartment that defines the human disease.
Limitations: Neither this line nor the alpha/beta line develops the cytoplasmic vacuolar inclusions in fibrocytes and mesenchymal cells - the I-cells - that characterise the skeletal and connective-tissue disease in human ML II and ML III. The predominant murine lesion is in exocrine secretory epithelium instead, which is not where the human disease is felt. This line is also reported to lack cartilage defects outright, which a second gamma-null line contradicts; see the cartilage controversy recorded in this entry. Storage-burden or connective-tissue endpoints should not be transferred from this model to patients.
Readouts
Cytoplasmic vacuolar inclusions in fibrocytes and mesenchymal cells (I-cells)
Direction: UNCHANGED
Interpretation: A negative result, and the reason this link is PARTIALLY_RECAPITULATES at LOW fidelity. The lesion that names the human disease does not form in either mouse line.
Show evidence (1 reference)
PMID:19261645 SUPPORT Model Organism
"Of significance, neither strain of mutant mice developed cytoplasmic vacuolar inclusions in fibrocytes or mesenchymal cells (I-cells), the characteristic lesion associated with the prominent skeletal and connective tissue abnormalities in humans with MLII and MLIII."
Documents the absent I-cell lesion in both knockout lines.
Show evidence (1 reference)
PMID:19261645 SUPPORT Model Organism
"We conclude that mice lacking either alpha/beta or gamma subunits displayed clinical and pathologic features that differed substantially from those reported in humans having mutations in orthologous genes."
The authors' own bound on how far either mouse line stands in for the human connective-tissue disease.
Notes
MGI records Gnptg<tm1Lex> (MGI:3757947, Lexicon Genetics) with PMID:17652091 as its originating reference and annotates that paper to this genotype, so the phosphorylation measurement below is allele-confirmed. MGI carries no annotation for PMID:19261645; that paper is assigned to this line on author and allele-series continuity with PMID:17652091 rather than on an MGI record, and the assignment should be treated as such. A separate gamma-null line from a different group is curated below, and the two disagree about cartilage.
Gnptg-null mouse, Hamburg line (Gnptg ko)
A second, independently derived gamma-subunit null line, curated separately from the Lexicon line above because it is a different mouse. The reporting paper's Animals section states that its Gnptg ko (C57Bl/6) mice "have been described previously (Kollmann et al., 2012, 2013; Di Lorenzo et al., 2018)", a provenance distinct from the Lexicon allele. It is the line in which the cartilage and joint phenotype was found.
Species
Mouse
Genotype
Gnptg ko, homozygous
Background
C57BL/6
Genes
GNPTG hgnc:23026 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns GNPTG (hgnc:23026). hgnc:23026 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:33023972
Pathograph links
Lysosomal Substrate Accumulation in Connective Tissue partially recapitulates fidelity: moderate observes: organism Substrate accumulates inside chondrocytes and the cartilage matrix is altered, which is the connective-tissue storage this node names.
Limitations: Chondrocytes and tendon were assayed; the I-cell inclusions in fibrocytes and mesenchymal cells that define the human lesion were not reported here and were absent in the Lexicon line. The Lexicon line is reported to lack cartilage defects altogether, so this readout is contradicted by the other gamma-null model in this entry.
Readouts
Chondrocyte chondroitin sulfate content and differentiation
Direction: INCREASED
Interpretation: Substrate accumulating inside the cell type that builds cartilage, with differentiation impaired alongside it.
Show evidence (1 reference)
PMID:33023972 SUPPORT Model Organism
"missorting of a number of lysosomal enzymes is associated with intracellular accumulation of chondroitin sulfate in Gnptgko chondrocytes and their impaired differentiation, as well as with altered microstructure of the cartilage extracellular matrix (ECM)"
Reports the substrate accumulation and matrix change in cartilage in this line.
Notes
The allele is not named in the paper's abstract, and the full text is not in the local reference cache, so the line is recorded as the authors write it rather than by MGI allele symbol. MGI lists Gnptg<tm1d(KOMP)Wtsi> (MGI:6270380) with the synonym Gnptg<ko> and Di Lorenzo 2018 (PMID:29773673) as its reference, which is the plausible MGI identity for this line, but the match is not asserted here because it has not been confirmed against the paper.
{ }

Source YAML

click to show 
name: GNPTG-Mucolipidosis
creation_date: "2026-06-13T00:00:00Z"
description: >-
  GNPTG-mucolipidosis (mucolipidosis III gamma) is the attenuated form of
  GlcNAc-1-phosphotransferase deficiency, caused by biallelic variants in GNPTG encoding the
  gamma subunit of the enzyme that initiates mannose-6-phosphate (M6P) tagging of soluble
  lysosomal hydrolases. Loss of M6P tagging missorts and hypersecretes lysosomal enzymes,
  leaving lysosomes functionally deficient and causing slowly progressive substrate
  accumulation. It is a slowly progressive disorder mainly affecting skeletal, joint, and
  connective tissues, generally milder than GNPTAB-related mucolipidosis, with survival into
  adulthood and relatively preserved cognition.
category: Mendelian
disease_term:
  preferred_term: GNPTG-mucolipidosis
  term:
    id: MONDO:0009652
    label: GNPTG-mucolipidosis
classifications:
  isds_skeletal_category:
  - classification_value: lysosomal_storage_with_skeletal_involvement
    notes: >-
      ISDS Nosology and Classification of Genetic Skeletal Disorders, 2019
      revision (Mortier et al., PMID:31633310), Table 1 group 27 "Lysosomal
      storage diseases with skeletal involvement (dysostosis multiplex group)";
      listed as "Mucolipidosis III (pseudo-Hurler polydystrophy), gamma type".
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0009652
      label: GNPTG-mucolipidosis
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO disease identifier for this mucolipidosis III gamma entry.
references:
- reference: PMID:20301784
  title: "Mucolipidosis III Gamma."
  tags:
  - GeneReviews
synonyms:
- Mucolipidosis III gamma
- Mucolipidosis type IIIC
- Pseudo-Hurler polydystrophy, gamma
- GNPTG deficiency
parents:
- Lysosomal Storage Disorder
pathophysiology:
- name: GlcNAc-1-Phosphotransferase Gamma-Subunit Deficiency and M6P Targeting Failure
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Hydrolase or Cofactor Deficiency"
  biological_scale: MOLECULAR
  description: >-
    Biallelic GNPTG variants impair the gamma subunit of GlcNAc-1-phosphotransferase,
    reducing mannose-6-phosphate tagging of soluble acid hydrolases. Untagged enzymes are
    missorted and hypersecreted into plasma rather than delivered to the lysosome, leaving
    the lysosome functionally deficient in multiple hydrolases.
  gene:
    preferred_term: GNPTG
    term:
      id: hgnc:23026
      label: GNPTG
  biological_processes:
  - preferred_term: protein targeting to lysosome
    term:
      id: GO:0006622
      label: protein targeting to lysosome
    modifier: DECREASED
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  evidence:
  - reference: PMID:34172897
    reference_title: "Mucolipidosis type II and type III: a systematic review of 843 published cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mucolipidosis (ML) II, MLIII alpha/beta, and MLIII gamma are rare\nautosomal recessive lysosomal storage disorders."
    explanation: "Mucolipidosis III gamma is a lysosomal storage disorder in the GlcNAc-1-phosphotransferase spectrum."
  - reference: PMID:30882951
    reference_title: "The lysosomal storage disorders mucolipidosis type II, type III alpha/beta, and type III gamma: Update on GNPTAB and GNPTG mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MLIII alpha/beta and MLIII gamma are\nattenuated forms of the disease"
    explanation: "GNPTG-related ML III gamma is an attenuated form within the GNPTAB/GNPTG disease spectrum."
  downstream:
  - target: Lysosomal Substrate Accumulation in Connective Tissue
    description: Functional lysosomal hydrolase deficiency leads to substrate accumulation.
- name: Lysosomal Substrate Accumulation in Connective Tissue
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
  biological_scale: TISSUE
  description: >-
    Functional deficiency of multiple lysosomal hydrolases leads to slowly progressive
    accumulation of undegraded substrates, predominantly affecting skeletal, joint, and
    connective tissues.
  biological_processes:
  - preferred_term: lysosomal transport
    term:
      id: GO:0007041
      label: lysosomal transport
    modifier: ABNORMAL
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mucolipidosis III gamma (ML IIIγ) is a slowly progressive inborn error of metabolism mainly affecting skeletal, joint, and connective tissues."
    explanation: "Substrate accumulation predominantly affects skeletal, joint, and connective tissues."
  downstream:
  - target: Skeletal dysplasia
    description: Connective-tissue and skeletal lysosomal storage produces progressive skeletal dysplasia.
  - target: Limitation of joint mobility
    description: Joint and connective-tissue involvement restricts mobility.
  - target: Chronic pain
    description: Progressive skeletal and joint disease produces chronic pain and functional impairment.
  - target: Cardiac valve disease
    description: Connective-tissue storage affects cardiac valves, producing valvular thickening and insufficiency.
  - target: Carpal tunnel syndrome
    description: Connective-tissue thickening can compress the median nerve in the carpal tunnel.
phenotypes:
- name: Skeletal dysplasia
  description: Progressive skeletal dysplasia (dysostosis) affecting the skeleton.
  phenotype_term:
    preferred_term: Skeletal dysplasia
    term:
      id: HP:0002652
      label: Skeletal dysplasia
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mucolipidosis III gamma (ML IIIγ) is a slowly progressive inborn error of metabolism mainly affecting skeletal, joint, and connective tissues."
    explanation: "Skeletal involvement is a major feature."
- name: Limitation of joint mobility
  description: Progressive joint stiffness and restriction of movement.
  phenotype_term:
    preferred_term: Limitation of joint mobility
    term:
      id: HP:0001376
      label: Limitation of joint mobility
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mainly affecting skeletal, joint, and connective tissues"
    explanation: "Joint involvement with progressive restriction is characteristic."
- name: Chronic pain
  description: Significant morbidity from chronic pain with severe functional impairment.
  phenotype_term:
    preferred_term: Chronic pain
    term:
      id: HP:0012532
      label: Chronic pain
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe functional impairment and significant morbidity from chronic\npain"
    explanation: Chronic pain is a major source of morbidity in ML III gamma.
- name: Cardiac valve disease
  description: Thickening and insufficiency of the mitral and aortic valves, usually mild.
  phenotype_term:
    preferred_term: Mitral regurgitation
    term:
      id: HP:0001653
      label: Mitral regurgitation
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "thickening and insufficiency of the mitral and aortic valves"
    explanation: Cardiac valve thickening and insufficiency occur in ML III gamma.
- name: Carpal tunnel syndrome
  description: Carpal tunnel syndrome may require surgical release.
  phenotype_term:
    preferred_term: Constrictive median neuropathy
    term:
      id: HP:0012185
      label: Constrictive median neuropathy
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "carpal tunnel and, rarely, tarsal tunnel syndrome may\nrequire surgica"
    explanation: Carpal tunnel syndrome is a recognized complication requiring surgical management.
- name: Restrictive lung disease
  description: >
    Restrictive lung disease arising from thoracic (chest wall/skeletal)
    involvement; a rarely clinically significant cardiorespiratory
    complication.
  phenotype_term:
    preferred_term: Restrictive ventilatory defect
    term:
      id: HP:0002091
      label: Restrictive ventilatory defect
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "restrictive lung disease from thoracic"
    explanation: GeneReviews reports restrictive lung disease from thoracic involvement as a cardiorespiratory complication of ML III gamma.
- name: Aortic valve insufficiency
  description: >
    Thickening and insufficiency (regurgitation) of the aortic valve;
    accompanies the mitral valve involvement and is usually mild.
  phenotype_term:
    preferred_term: Aortic regurgitation
    term:
      id: HP:0001659
      label: Aortic regurgitation
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "thickening and insufficiency of the mitral and aortic valves"
    explanation: GeneReviews reports thickening and insufficiency of the aortic (as well as mitral) valve in ML III gamma.
- name: Motor delay
  description: >
    Delayed acquisition of motor milestones secondary to progressive
    joint disease.
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Motor milestones can be affected due to joint"
    explanation: GeneReviews attributes affected motor milestones to joint disease in ML III gamma.
- name: Cognitive impairment
  description: >
    Mild cognitive impairment reported in a small minority (probably <5%)
    of affected individuals.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  frequency: VERY_RARE
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A few (probably <5%) affected individuals display mild cognitive"
    explanation: GeneReviews reports mild cognitive impairment in a minority (<5%) of individuals with ML III gamma.
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:34172897
    reference_title: "Mucolipidosis type II and type III: a systematic review of 843 published cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "rare\nautosomal recessive lysosomal storage disorders"
    explanation: "Mucolipidosis III gamma is autosomal recessive."
genetic:
- name: GNPTG
  association: Biallelic GNPTG variants impairing the GlcNAc-1-phosphotransferase gamma subunit
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  gene_term:
    preferred_term: GNPTG
    term:
      id: hgnc:23026
      label: GNPTG
  evidence:
  - reference: PMID:30882951
    reference_title: "The lysosomal storage disorders mucolipidosis type II, type III alpha/beta, and type III gamma: Update on GNPTAB and GNPTG mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GNPTAB and GNPTG encode the α/β-precursor and the\nγ-subunit of N-acetylglucosamine (GlcNAc)-1-phosphotransferase, respectively"
    explanation: "GNPTG encodes the gamma subunit of GlcNAc-1-phosphotransferase; its biallelic loss causes ML III gamma."
diagnosis:
- name: Plasma lysosomal enzyme activity and GNPTG sequencing
  diagnosis_term:
    preferred_term: clinical laboratory procedure
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  description: >-
    Markedly elevated activities of multiple lysosomal enzymes in plasma/serum (from
    hypersecretion) with reduced intracellular activity suggests a mannose-6-phosphate
    targeting defect; diagnosis is confirmed by GNPTG sequencing.
  markers: Elevated plasma lysosomal enzyme activities with reduced intracellular activity.
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of ML IIIγ is established in a proband with\nsuggestive clinical and radiographic findings and biallelic pathogenic variants\nin GNPTG identified by molecular genetic testing"
    explanation: "Diagnosis combines suggestive clinical/radiographic findings with biallelic GNPTG variants on molecular testing."
- name: GNPTG molecular genetic testing
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: Confirmatory biallelic GNPTG sequencing.
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants\nin GNPTG identified by molecular genetic testing"
    explanation: "Biallelic GNPTG variants on molecular genetic testing provide diagnostic confirmation."
differential_diagnoses:
- name: Mucolipidosis type II
  description: >-
    The severe end of the GlcNAc-1-phosphotransferase spectrum (GNPTAB), with infantile onset
    and early death.
  disease_term:
    preferred_term: mucolipidosis type II
    term:
      id: MONDO:0009650
      label: mucolipidosis type II
  distinguishing_features:
  - GNPTAB defects with severe infantile-onset disease and death in early childhood, versus the attenuated GNPTG form.
  evidence:
  - reference: PMID:34172897
    reference_title: "Mucolipidosis type II and type III: a systematic review of 843 published cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mucolipidosis (ML) II, MLIII alpha/beta, and MLIII gamma are rare\nautosomal recessive lysosomal storage disorders."
    explanation: "ML II and ML III gamma are distinct severities within the same phosphotransferase spectrum."
treatments:
- name: Supportive Care
  description: >-
    No disease-modifying therapy is established; management is supportive, with orthopedic
    and physiotherapeutic care for the musculoskeletal disease.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Braces (especially of the hands) at night may\nimprove daily functions"
    explanation: Supportive measures such as night braces improve daily function in ML III gamma.
- name: Bisphosphonate Therapy
  description: >-
    Bisphosphonate treatment is used in individuals with significant skeletal disease and
    bone pain.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bisphosphonate treatment in individuals with significant\nskeletal dis"
    explanation: Bisphosphonates are used for the significant skeletal disease and bone pain.
- name: Joint Replacement Surgery
  description: >-
    Joint replacement (especially hip and knee) relieves pain and improves function in older
    adolescents and adults.
  treatment_term:
    preferred_term: joint replacement
    term:
      id: NCIT:C131579
      label: Joint Replacement
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "joint replacement has\nbeen successful in relieving hip pain and knee"
    explanation: Joint replacement successfully relieves hip and knee pain in ML III gamma.
- name: Pain Management
  description: >-
    As skeletal disease intensifies, management focuses on pain relief, including for
    chronic pain.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "management\nfocuses on pain relief"
    explanation: Pain relief is a central component of ML III gamma management.
definitions:
- name: Clinical case definition of mucolipidosis III gamma
  definition_type: CASE_DEFINITION
  description: >-
    Mucolipidosis III gamma is the attenuated GlcNAc-1-phosphotransferase deficiency caused by
    biallelic GNPTG variants, defined by a mannose-6-phosphate targeting defect with slowly
    progressive skeletal, joint, and connective-tissue disease.
  scope: Disease-level case definition for GNPTG-mucolipidosis (ML III gamma).
  evidence:
  - reference: PMID:20301784
    reference_title: "Mucolipidosis III Gamma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mucolipidosis III gamma (ML IIIγ) is a slowly progressive inborn error of metabolism mainly affecting skeletal, joint, and connective tissues."
    explanation: "Anchors the case definition in the GNPTG-related connective-tissue mucolipidosis."
animal_models:
- name: Gnptg-null mouse, Lexicon line (Gnptg tm1Lex)
  species: Mouse
  genotype: Gnptg<tm1Lex>/Gnptg<tm1Lex>
  alleles:
  - Gnptg<tm1Lex>
  genes:
  - preferred_term: GNPTG
    term:
      id: hgnc:23026
      label: GNPTG
  publication: PMID:19261645
  description: >-
    Knockout of the GlcNAc-1-phosphotransferase gamma subunit, studied alongside
    the alpha/beta-subunit knockout that models mucolipidosis II. The pairing is
    what makes this model informative: losing the gamma subunit causes only a
    partial loss of mannose-6-phosphate tagging, where losing alpha/beta abolishes
    it, and the severity of storage disease in the two lines tracks the residual
    enzyme activity. That graded relationship is the mouse counterpart of the
    milder human ML III gamma against ML II.
  notes: >-
    MGI records Gnptg<tm1Lex> (MGI:3757947, Lexicon Genetics) with PMID:17652091
    as its originating reference and annotates that paper to this genotype, so
    the phosphorylation measurement below is allele-confirmed. MGI carries no
    annotation for PMID:19261645; that paper is assigned to this line on author
    and allele-series continuity with PMID:17652091 rather than on an MGI record,
    and the assignment should be treated as such. A separate gamma-null line from
    a different group is curated below, and the two disagree about cartilage.
  modeled_mechanisms:
  - target: GlcNAc-1-Phosphotransferase Gamma-Subunit Deficiency and M6P Targeting
      Failure
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: ORGANISM
    description: >-
      Germline loss of the orthologous subunit, with the partial rather than
      complete tagging defect that distinguishes gamma-subunit disease from
      alpha/beta-subunit disease.
    limitations: >-
      A complete gamma-subunit null models the severe end of the GNPTG allelic
      spectrum, whereas most human ML III gamma alleles retain some subunit
      function.
    readouts:
    - name: Mannose 6-phosphorylation of acid hydrolases
      target: GlcNAc-1-Phosphotransferase Gamma-Subunit Deficiency and M6P Targeting
        Failure
      direction: DECREASED
      interpretation: >-
        Partial, not abolished. The same study measured complete loss in the
        alpha/beta knockout, so this readout is the quantitative difference
        between ML III gamma and ML II rather than a shared defect.
      evidence:
      - reference: PMID:17652091
        reference_title: 'Murine UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase
          lacking the gamma-subunit retains substantial activity toward acid hydrolases.'
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: disruption of the alpha/beta gene completely abolishes phosphorylation
          of high mannose oligosaccharides on acid hydrolases whereas knock-out of
          the gamma gene results in only a partial loss of phosphorylation
        explanation: Measures the residual phosphotransferase activity in this genotype
          against the alpha/beta null assayed in the same study.
    - name: Serum lysosomal enzyme levels
      target: GlcNAc-1-Phosphotransferase Gamma-Subunit Deficiency and M6P Targeting
        Failure
      direction: INCREASED
      interpretation: >-
        Enzyme amount rising in the wrong compartment because the tagging that
        routes hydrolases to the lysosome is impaired. It must not be read as
        preserved lysosomal function.
      evidence:
      - reference: PMID:19261645
        reference_title: Comparative pathology of murine mucolipidosis types II and
          IIIC.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: We found that both lines of mutant mice had elevated levels of serum
          lysosomal enzymes and cytoplasmic alterations in secretory cells of several
          exocrine glands; however, lesions in gamma-subunit deficient (Gnptg(-/-))
          mice were milder and more restricted in distribution than in alpha/beta-subunit
          deficient (Gnptab(-/-)) mice.
        explanation: Reports the raised circulating hydrolases and the milder, more
          restricted lesion distribution relative to the alpha/beta null.
    evidence:
    - reference: PMID:19261645
      reference_title: Comparative pathology of murine mucolipidosis types II and IIIC.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: The milder disease in the gamma-subunit deficient mice correlated with
        residual synthesis of the mannose 6-phosphate recognition marker.
      explanation: Ties the milder phenotype directly to residual M6P tagging, which
        is the mechanism this node names.
  - target: Lysosomal Substrate Accumulation in Connective Tissue
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    model_scale: ORGANISM
    description: >-
      Storage develops, but not in the tissue compartment that defines the human
      disease.
    limitations: >-
      Neither this line nor the alpha/beta line develops the cytoplasmic vacuolar
      inclusions in fibrocytes and mesenchymal cells - the I-cells - that
      characterise the skeletal and connective-tissue disease in human ML II and
      ML III. The predominant murine lesion is in exocrine secretory epithelium
      instead, which is not where the human disease is felt. This line is also
      reported to lack cartilage defects outright, which a second gamma-null line
      contradicts; see the cartilage controversy recorded in this entry.
      Storage-burden or connective-tissue endpoints should not be transferred from
      this model to patients.
    readouts:
    - name: Cytoplasmic vacuolar inclusions in fibrocytes and mesenchymal cells (I-cells)
      target: Lysosomal Substrate Accumulation in Connective Tissue
      direction: UNCHANGED
      interpretation: >-
        A negative result, and the reason this link is PARTIALLY_RECAPITULATES at
        LOW fidelity. The lesion that names the human disease does not form in
        either mouse line.
      evidence:
      - reference: PMID:19261645
        reference_title: Comparative pathology of murine mucolipidosis types II and
          IIIC.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: Of significance, neither strain of mutant mice developed cytoplasmic
          vacuolar inclusions in fibrocytes or mesenchymal cells (I-cells), the characteristic
          lesion associated with the prominent skeletal and connective tissue abnormalities
          in humans with MLII and MLIII.
        explanation: Documents the absent I-cell lesion in both knockout lines.
    evidence:
    - reference: PMID:19261645
      reference_title: Comparative pathology of murine mucolipidosis types II and IIIC.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We conclude that mice lacking either alpha/beta or gamma subunits displayed
        clinical and pathologic features that differed substantially from those reported
        in humans having mutations in orthologous genes.
      explanation: The authors' own bound on how far either mouse line stands in for
        the human connective-tissue disease.
- name: Gnptg-null mouse, Hamburg line (Gnptg ko)
  species: Mouse
  genotype: Gnptg ko, homozygous
  background: C57BL/6
  genes:
  - preferred_term: GNPTG
    term:
      id: hgnc:23026
      label: GNPTG
  publication: PMID:33023972
  description: >-
    A second, independently derived gamma-subunit null line, curated separately
    from the Lexicon line above because it is a different mouse. The reporting
    paper's Animals section states that its Gnptg ko (C57Bl/6) mice "have been
    described previously (Kollmann et al., 2012, 2013; Di Lorenzo et al., 2018)",
    a provenance distinct from the Lexicon allele. It is the line in which the
    cartilage and joint phenotype was found.
  notes: >-
    The allele is not named in the paper's abstract, and the full text is not in
    the local reference cache, so the line is recorded as the authors write it
    rather than by MGI allele symbol. MGI lists Gnptg<tm1d(KOMP)Wtsi>
    (MGI:6270380) with the synonym Gnptg<ko> and Di Lorenzo 2018 (PMID:29773673)
    as its reference, which is the plausible MGI identity for this line, but the
    match is not asserted here because it has not been confirmed against the
    paper.
  modeled_mechanisms:
  - target: Lysosomal Substrate Accumulation in Connective Tissue
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    description: >-
      Substrate accumulates inside chondrocytes and the cartilage matrix is
      altered, which is the connective-tissue storage this node names.
    limitations: >-
      Chondrocytes and tendon were assayed; the I-cell inclusions in fibrocytes
      and mesenchymal cells that define the human lesion were not reported here
      and were absent in the Lexicon line. The Lexicon line is reported to lack
      cartilage defects altogether, so this readout is contradicted by the other
      gamma-null model in this entry.
    readouts:
    - name: Chondrocyte chondroitin sulfate content and differentiation
      target: Lysosomal Substrate Accumulation in Connective Tissue
      direction: INCREASED
      interpretation: >-
        Substrate accumulating inside the cell type that builds cartilage, with
        differentiation impaired alongside it.
      evidence:
      - reference: PMID:33023972
        reference_title: Imbalanced cellular metabolism compromises cartilage homeostasis
          and joint function in a mouse model of mucolipidosis type III gamma.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: missorting of a number of lysosomal enzymes is associated with intracellular
          accumulation of chondroitin sulfate in Gnptgko chondrocytes and their impaired
          differentiation, as well as with altered microstructure of the cartilage
          extracellular matrix (ECM)
        explanation: Reports the substrate accumulation and matrix change in cartilage
          in this line.
  - target: Chronic pain
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    model_scale: ORGANISM
    description: >-
      A functional joint deficit that the authors attribute to fatigue or pain at
      the joint, which is the closest available model correlate of the chronic
      joint pain reported by patients.
    limitations: >-
      Rotarod performance under fatigue is a composite motor readout, not a pain
      measurement. The authors offer fatigue or pain as alternative explanations
      and do not separate them, and no nociceptive assay was performed, so this
      link rests on the authors' interpretation rather than on a direct measure of
      pain.
    readouts:
    - name: Limb motor performance on rotarod under fatigue
      target: Chronic pain
      direction: DECREASED
      interpretation: >-
        Reduced endurance on the rotarod under fatigue conditions, taken as a
        whole-animal functional measure of how well the joint bears sustained
        load.
      evidence:
      - reference: PMID:33023972
        reference_title: Imbalanced cellular metabolism compromises cartilage homeostasis
          and joint function in a mouse model of mucolipidosis type III gamma.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: This idea was supported by a deficit of the limb motor function in
          Gnptgko mice challenged on a rotarod under fatigue-associated conditions,
          suggesting that the impaired motor performance of Gnptgko mice was caused
          by fatigue and/or pain at the joint.
        explanation: Reports the motor deficit and the authors' attribution of it to
          fatigue or joint pain.
    evidence:
    - reference: PMID:33023972
      reference_title: Imbalanced cellular metabolism compromises cartilage homeostasis
        and joint function in a mouse model of mucolipidosis type III gamma.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Patients with MLIII gamma typically present with osteoarthritis and
        joint stiffness, suggesting cartilage involvement.
      explanation: States the human joint phenotype this model is being used to represent.
discussions:
- discussion_id: gnptg_mouse_cartilage_conflict
  kind: CONTROVERSY
  status: OPEN
  prompt: Do Gnptg-null mice have a cartilage phenotype?
  attaches_to:
  - animal_models#Gnptg-null mouse, Lexicon line (Gnptg tm1Lex)
  - animal_models#Gnptg-null mouse, Hamburg line (Gnptg ko)
  - pathophysiology#Lysosomal Substrate Accumulation in Connective Tissue
  rationale: >-
    Two reports of gamma-subunit null mice reach opposite conclusions. The 2009
    comparative pathology study reports that the gamma-null mice "lacked cartilage
    defects", and uses that absence, with the absent retinal degeneration, to argue
    the line is milder than the alpha/beta knockout. The 2020 study reports
    intracellular chondroitin sulfate accumulation in Gnptg knockout chondrocytes,
    impaired chondrocyte differentiation, and altered cartilage extracellular
    matrix microstructure. Four candidate explanations are on the table and none
    has been tested against the others. First, the two papers do not use the same
    mouse: the 2020 Animals section attributes its line to Kollmann and Di Lorenzo,
    a different provenance from the Lexicon allele carrying the 2009 result, so
    line and background differences are a live explanation rather than a
    formality. Second, depth of assay differs - the earlier study read histology
    and gross phenotype, the later one measured matrix ultrastructure, substrate
    content and chondrocyte differentiation, so a defect invisible at one
    resolution may be plain at another. Third, the 2009 authors offer their own
    mechanistic account, attributing the absent chondrocyte and retinal lesions to
    residual beta-glucuronidase activity, which is a residual-activity explanation
    of the same kind that organises the rest of this entry. Fourth, the animals may
    not be of comparable age: the 2020 work reports on aged joints and tendon,
    while the 2009 abstract does not state its timepoints. Recorded so the entry
    does not silently adopt one report over the other.
  evidence:
  - reference: PMID:19261645
    reference_title: Comparative pathology of murine mucolipidosis types II and IIIC.
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: In contrast to mice deficient in the alpha/beta subunits, the mice lacking
      the gamma subunits were of normal size, lacked cartilage defects, and did not
      develop retinal degeneration.
    explanation: The report that the Lexicon line has no cartilage defect.
  - reference: PMID:19261645
    reference_title: Comparative pathology of murine mucolipidosis types II and IIIC.
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: The absence of retinal and chondrocyte lesions in Gnptg(-/-) mice might
      be attributed to residual beta-glucuronidase activity.
    explanation: The sentence presupposes the absent chondrocyte lesions in order
      to explain them, so it asserts the absence as well as accounting for it. Its
      distinctive content is that account - residual beta-glucuronidase activity -
      which the rationale carries as one of the four candidate explanations.
  - reference: PMID:33023972
    reference_title: Imbalanced cellular metabolism compromises cartilage homeostasis
      and joint function in a mouse model of mucolipidosis type III gamma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: missorting of a number of lysosomal enzymes is associated with intracellular
      accumulation of chondroitin sulfate in Gnptgko chondrocytes and their impaired
      differentiation, as well as with altered microstructure of the cartilage extracellular
      matrix (ECM)
    explanation: The report that a gamma-null line does have a cartilage phenotype.
  proposed_experiments:
  - experiment_id: gnptg_cartilage_head_to_head_matched_age
    name: Both gamma-null lines assayed side by side at matched ages with the deeper
      cartilage endpoints
    description: >-
      Take the Lexicon line and the Hamburg line into one experiment and apply the
      2020 endpoints to both at the same ages: chondrocyte chondroitin sulfate
      content, chondrocyte differentiation markers, and cartilage extracellular
      matrix ultrastructure, alongside the histology and gross skeletal assessment
      the 2009 study used. This is the one design that separates the first two
      candidate explanations from each other, because a line difference and a
      depth-of-assay difference make opposite predictions once line and assay are
      varied independently.
    would_support:
    - pathophysiology#Lysosomal Substrate Accumulation in Connective Tissue
    supporting_outcome:
    - >-
      Both lines show chondroitin sulfate accumulation and matrix change at the
      deeper endpoints while both remain unremarkable on histology alone, which
      would make depth of assay the explanation and the cartilage phenotype a
      property of gamma-subunit loss rather than of one line.
    would_refute:
    - pathophysiology#Lysosomal Substrate Accumulation in Connective Tissue
    refuting_outcome:
    - >-
      The Hamburg line reproduces the 2020 findings and the Lexicon line remains
      unaffected at the same endpoints and ages, which would make the line
      difference the explanation and leave the cartilage phenotype unestablished
      for gamma-subunit loss in general.
  - experiment_id: gnptg_residual_beta_glucuronidase_in_cartilage
    name: Residual beta-glucuronidase activity in cartilage of both gamma-null lines
    description: >-
      Measure beta-glucuronidase activity in chondrocytes and cartilage of both
      lines against wild-type and against the alpha/beta knockout, to test the 2009
      authors' own account of the absence they report. The claim is currently an
      untested hypothesis offered in a discussion sentence, and it is the candidate
      explanation most directly checkable, since the residual activity it invokes
      is a quantity rather than a difference in husbandry or method.
    supporting_outcome:
    - >-
      Residual beta-glucuronidase activity in cartilage tracks inversely with
      cartilage involvement across the lines, supporting a graded-activity
      threshold above which the tissue is spared.
    refuting_outcome:
    - >-
      Residual beta-glucuronidase activity is comparable in the two lines despite
      their differing cartilage findings, which would eliminate the 2009 authors'
      account and leave line provenance, assay depth or animal age carrying the
      discrepancy.
📚

References & Deep Research

References

1
PMID:20301784
Mucolipidosis III Gamma.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 32 citations 2026-06-13T15:14:08.228490

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: GNPTG-Mucolipidosis
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on GNPTG-Mucolipidosis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

GNPTG‑Mucolipidosis (Mucolipidosis type III gamma; MLIIIγ): Comprehensive disease characteristics report

Executive summary

GNPTG‑mucolipidosis corresponds to mucolipidosis type III gamma (MLIIIγ), an autosomal recessive lysosomal storage disorder caused by biallelic pathogenic variants in GNPTG, encoding the γ subunit of N‑acetylglucosamine‑1‑phosphotransferase (GlcNAc‑1‑PT)—the initiating enzyme for mannose‑6‑phosphate (M6P) tagging of lysosomal hydrolases. Loss of proper M6P tagging causes missorting and hypersecretion of lysosomal enzymes into extracellular fluids (plasma/serum), with relative deficiency in lysosomes, leading to progressive connective‑tissue/bone/joint disease that is typically milder than GNPTAB‑related mucolipidosis. (velho2019thelysosomalstorage pages 1-3, dogterom2021mucolipidosistypeii pages 1-2)

Recent (2023–2024) advances relevant to GNPTG‑mucolipidosis include: (i) multiplex tandem mass spectrometry assays in dried blood spots to support screening/diagnosis of MLII/III; and (ii) whole‑genome sequencing (WGS) enabling diagnosis in atypical presentations and expanding the phenotype to include late‑onset retinal dystrophy/retinitis pigmentosa in at least one GNPTG‑confirmed case. (hong2023multiplextandemmass pages 1-2, geer2023unravelingmucolipidosistype pages 2-5)

1. Disease information

1.1 Definition and overview

Mucolipidosis type III gamma (MLIIIγ) is an attenuated mucolipidosis within the MLII/III spectrum, caused by defects in the lysosomal enzyme targeting pathway (M6P tagging). It is described as a variable but generally milder phenotype than MLII and MLIIIα/β, with major manifestations in the musculoskeletal system (progressive joint restriction, skeletal dysplasia/degeneration). (velho2019thelysosomalstorage pages 1-3, dogterom2021mucolipidosistypeii pages 1-2)

1.2 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

The retrieved full‑text evidence did not include OMIM, Orphanet, ICD‑10/ICD‑11, MeSH, or MONDO identifiers; therefore these cannot be reported with tool‑verified citations in this run.

1.3 Synonyms and alternative names

  • Mucolipidosis type III gamma (MLIIIγ). (velho2019thelysosomalstorage pages 1-3, dogterom2021mucolipidosistypeii pages 1-2)
  • Historical MLIII literature uses pseudo‑Hurler polydystrophy (used in GNPTG mutation papers). (persichetti2009identificationandmolecular pages 1-2)

1.4 Evidence source types

  • Aggregated disease‑level resources: systematic review of 843 cases and a GNPTAB/GNPTG mutation update compiling hundreds of individuals. (dogterom2021mucolipidosistypeii pages 1-2, velho2019thelysosomalstorage pages 1-3)
  • Individual patient reports: e.g., WGS‑diagnosed late‑onset retinitis pigmentosa case. (geer2023unravelingmucolipidosistype pages 1-2)
  • Model organism and cellular: Gnptg knockout mouse studies investigating cartilage/ECM and joint function. (westermann2020imbalancedcellularmetabolism pages 42-44)

2. Etiology

2.1 Disease causal factors

Primary cause: biallelic pathogenic variants in GNPTG (autosomal recessive). (velho2019thelysosomalstorage pages 1-3, dogterom2021mucolipidosistypeii pages 1-2)

Molecular cause: GNPTG encodes the γ subunit of the α2β2γ2 GlcNAc‑1‑phosphotransferase complex that initiates formation of M6P on lysosomal enzymes. Reduced function causes defective M6P tagging, missorting and extracellular secretion of lysosomal hydrolases, and downstream lysosomal substrate accumulation. (velho2019thelysosomalstorage pages 1-3, dogterom2021mucolipidosistypeii pages 1-2, khan2020mucolipidosesoverviewpast pages 3-6)

2.2 Risk factors

  • Genetic: biallelic GNPTG pathogenic variants are causal. (dogterom2021mucolipidosistypeii pages 1-2, velho2019thelysosomalstorage pages 1-3)

Environmental, lifestyle, or infectious risk factors were not identified in the retrieved evidence and are not generally expected for this Mendelian disorder.

2.3 Protective factors / gene–environment interactions

No protective genetic variants or gene–environment interactions were identified in the retrieved evidence.

3. Phenotypes

3.1 Core clinical phenotype spectrum

Across primary reports and systematic synthesis, MLIIIγ is characterized by predominant musculoskeletal and connective‑tissue disease: * Joint stiffness / restricted joint mobility (often progressive). (meel2016mucolipidosisiiignptg pages 1-3, dogterom2021mucolipidosistypeii pages 1-2) * Claw‑hand deformity and hand stiffness. (meel2016mucolipidosisiiignptg pages 1-3) * Short stature and scoliosis/kyphosis. (meel2016mucolipidosisiiignptg pages 1-3, persichetti2009identificationandmolecular pages 1-2) * Progressive bone/joint disease, including hip destruction; orthopedic sequelae can be severe (e.g., hip replacement by age 30 in one GNPTG‑confirmed adult). (geer2023unravelingmucolipidosistype pages 1-2) * Carpal/tarsal tunnel syndrome is reported as common among MLIII patients in systematic synthesis. (dogterom2021mucolipidosistypeii pages 1-2) * Cardiac valve disease (valvular involvement) can occur. (meel2016mucolipidosisiiignptg pages 1-3) * Neurocognition: generally normal intellectual capacity or only mild impairment in MLIII (including MLIIIγ) in systematic synthesis. (dogterom2021mucolipidosistypeii pages 1-2)

3.2 Phenotype expansion (2023)

A 2023 WGS‑diagnosed case reported late‑onset retinal dystrophy/retinitis pigmentosa in a man with compound heterozygous GNPTG pathogenic variants, and explicitly noted that retinal dystrophy was not previously a common feature; the authors stated it was (to their knowledge) the first description of retinitis pigmentosa due to GNPTG compound heterozygosity. (geer2023unravelingmucolipidosistype pages 1-2)

3.3 Age of onset, severity, progression

In MLII/III overall, MLIII has later onset and milder course than MLII; in a systematic review, median age at diagnosis for MLIII was 9.0 years (contrasting with 0.7 years for MLII). (dogterom2021mucolipidosistypeii pages 1-2)

3.4 Quality of life impact (evidence‑based inference)

Quality of life is likely driven by progressive joint restriction, pain, and orthopedic morbidity (e.g., joint replacements). A direct quantitative QoL instrument (e.g., SF‑36/EQ‑5D) was not identified in the retrieved evidence; QoL assertions therefore cannot be made quantitatively.

3.5 Suggested HPO terms (non‑exhaustive)

Based on the evidence‑supported phenotype spectrum: * Joint stiffness / limitation of joint mobility (HP:0001376 / HP:0001385) (meel2016mucolipidosisiiignptg pages 1-3, dogterom2021mucolipidosistypeii pages 1-2) * Short stature (HP:0004322) (meel2016mucolipidosisiiignptg pages 1-3) * Scoliosis (HP:0002650) (meel2016mucolipidosisiiignptg pages 1-3) * Osteoarthritis / degenerative joint disease (HP:0002758) (westermann2020imbalancedcellularmetabolism pages 42-44) * Carpal tunnel syndrome (HP:0001240? note: HPO exists as HP:0001240 is “Seizures”; therefore do not treat this as a definitive code; term suggested conceptually from the review) (dogterom2021mucolipidosistypeii pages 1-2) * Valvular heart disease (HP:0001654 conceptually) (meel2016mucolipidosisiiignptg pages 1-3) * Retinitis pigmentosa (HP:0000510) (geer2023unravelingmucolipidosistype pages 1-2)

(Where HPO IDs are marked “conceptually,” exact IDs should be verified against the HPO database; the provided evidence supports the clinical concept but does not provide ontology mappings.)

4. Genetic / molecular information

4.1 Causal gene

  • GNPTG encodes the soluble γ subunit of GlcNAc‑1‑phosphotransferase. (velho2019thelysosomalstorage pages 1-3, dogterom2021mucolipidosistypeii pages 1-2)

4.2 Pathogenic variant classes and functional consequences

Variant classes reported include missense, nonsense, splice‑site, and frameshift/microdeletion alleles. (persichetti2009identificationandmolecular pages 1-2)

Functional consequences (examples): * Multiple GNPTG missense variants (p.G106S, p.G126S, p.C142Y) cause misfolding, ER retention, and aggregation of the γ subunit, preventing functional rescue of lysosomal targeting. (meel2016mucolipidosisiiignptg pages 1-3) * Other pathogenic alleles can cause aberrant splicing or nonsense‑mediated decay, leading to loss of GNPTG protein synthesis. (persichetti2009identificationandmolecular pages 1-2)

4.3 Example variants from recent clinical reporting

In the 2023 late‑onset retinal dystrophy case, WGS identified compound heterozygous GNPTG pathogenic variants c.347_349del and c.607dup (protein consequences reported as p.Asn116del and p.Gln203fs in the evidence summary), motivating the MLIIIγ diagnosis. (geer2023unravelingmucolipidosistype pages 1-2)

4.4 Allele frequencies / population databases

Allele frequencies (gnomAD, 1000 Genomes, etc.) and carrier frequency estimates were not provided in the retrieved evidence.

4.5 Modifier genes / epigenetics / chromosomal abnormalities

No modifier genes, epigenetic mechanisms, or chromosomal abnormalities were identified in the retrieved evidence.

5. Environmental information

No environmental, lifestyle, or infectious contributors were identified in the retrieved evidence; MLIIIγ is primarily a Mendelian disorder driven by GNPTG genotype.

6. Mechanism / pathophysiology

6.1 Current mechanistic understanding

GlcNAc‑1‑phosphotransferase is the key enzyme initiating addition of the M6P targeting signal on lysosomal hydrolases. GNPTAB encodes the α/β precursor and GNPTG encodes the γ subunit in an α2β2γ2 complex; defective GlcNAc‑1‑PT leads to missorting of newly synthesized lysosomal enzymes into the extracellular space, causing a shortage in lysosomes and accumulation of non‑degradable macromolecules, impairing cellular function. (velho2019thelysosomalstorage pages 1-3, dogterom2021mucolipidosistypeii pages 1-2, khan2020mucolipidosesoverviewpast pages 3-6)

A systematic review emphasized that M6P is essential for targeting >70 soluble lysosomal enzymes, and without M6P, enzymes are secreted extracellularly. (dogterom2021mucolipidosistypeii pages 1-2)

6.2 Causal chain (trigger → molecular defect → cellular defect → organ disease)

1) Biallelic GNPTG pathogenic variants → defective γ subunit of GlcNAc‑1‑PT (often misfolding/ER retention or loss of transcript/protein). (meel2016mucolipidosisiiignptg pages 1-3, persichetti2009identificationandmolecular pages 1-2) 2) Reduced M6P tagging on subsets of lysosomal enzymes → missorting/hypersecretion of hydrolases into plasma/serum. (meel2016mucolipidosisiiignptg pages 1-3, dogterom2021mucolipidosistypeii pages 1-2) 3) Intralysosomal enzyme deficiency → storage of substrates in lysosomes (connective‑tissue relevant substrates include glycosaminoglycans/oligosaccharides, etc.). (dogterom2021mucolipidosistypeii pages 1-2, khan2020mucolipidosesoverviewpast pages 3-6) 4) Tissue dysfunction in cartilage/tendon/bone/connective tissue → progressive joint restriction, skeletal deformity/degeneration and pain. (westermann2020imbalancedcellularmetabolism pages 42-44)

6.3 Cellular processes and tissues/cell types implicated (supported by model data)

In a Gnptg knockout mouse model, joint pathology is linked to chondroitin sulfate accumulation in chondrocytes, impaired differentiation, and altered cartilage ECM microstructure; mechanosensitive connective tissues such as cartilage and tendon are highlighted. (westermann2020imbalancedcellularmetabolism pages 42-44)

Suggested GO biological process terms (conceptual; verify IDs): lysosomal enzyme targeting, lysosome organization, glycosaminoglycan catabolic process, extracellular matrix organization.

Suggested Cell Ontology (CL) cell types: chondrocyte; fibroblast.

7. Anatomical structures affected

7.1 Organ/tissue systems

Dominant involvement of musculoskeletal/connective tissue systems (joints, cartilage, tendon, bone) is supported by human phenotypes and mouse data. (dogterom2021mucolipidosistypeii pages 1-2, westermann2020imbalancedcellularmetabolism pages 42-44)

7.2 Subcellular localization

Primary dysfunction centers on the Golgi→lysosome trafficking axis (M6P tagging in Golgi) and downstream lysosomal substrate storage. (dogterom2021mucolipidosistypeii pages 1-2)

7.3 Suggested UBERON terms (conceptual)

Cartilage, tendon, bone, joint, retina.

8. Temporal development

8.1 Onset patterns

MLIII (including MLIIIγ) is typically recognized in childhood; MLIII average age‑of‑onset is cited as ~5 years in a 2023 diagnostic assay paper, but MLIIIγ may present variably and can be diagnosed later in atypical presentations. (hong2023multiplextandemmass pages 1-2, geer2023unravelingmucolipidosistype pages 1-2)

8.2 Disease course

MLIII is typically chronic and progressive. Median age at diagnosis in the systematic review was 9 years for MLIII, with long survival into adulthood for many patients. (dogterom2021mucolipidosistypeii pages 1-2)

9. Inheritance and population

9.1 Inheritance

Autosomal recessive. (velho2019thelysosomalstorage pages 1-3, dogterom2021mucolipidosistypeii pages 1-2)

9.2 Epidemiology (available data)

A 2023 MS/MS diagnostic assay paper reports combined MLII/III prevalence of 0.22–2.70 per 100,000 live births (not GNPTG‑specific). (hong2023multiplextandemmass pages 1-2)

9.3 Population genetics / founder effects

Carrier frequencies, penetrance estimates, and founder variants were not provided in the retrieved evidence.

10. Diagnostics

10.1 Biochemical testing (hallmark pattern)

A defining diagnostic hallmark across mucolipidosis II/III is elevated lysosomal enzyme activities in plasma/serum due to hypersecretion (with relative reduction/low‑normal activities in leukocytes/fibroblasts). (sohn2016moleculargeneticsand pages 1-2, meel2016mucolipidosisiiignptg pages 1-3)

Quantitative example (GNPTG case, 2023): plasma β‑glucuronidase 1370 µkat/L vs 42 control; Hexosaminidase B 5190 vs 135; β‑galactosidase 4.2 vs 0.9; leukocyte activities were slightly decreased or low‑normal. (geer2023unravelingmucolipidosistype pages 2-5)

10.2 Genetic testing

Molecular confirmation requires GNPTG sequencing (and GNPTAB to subtype within MLII/III), because biochemical enzyme elevations alone do not reliably distinguish MLII vs MLIII subtypes. (khan2020mucolipidosesoverviewpast pages 3-6, hong2023multiplextandemmass pages 2-4)

WGS as implementation example (2023): a 325‑gene retinal disease panel filter applied to WGS data unexpectedly identified GNPTG pathogenic variants, leading to MLIIIγ diagnosis in a retinitis pigmentosa presentation. (geer2023unravelingmucolipidosistype pages 1-2)

10.3 Screening / new diagnostic developments (2023)

A 2023 study developed a multiplex UPLC‑MS/MS enzyme activity assay using two 6‑plex panels on dried blood spots (12 enzymes total). In MLII/III DBS samples, ASM, IDS, and NAGLU were markedly elevated (about 20‑, 11‑, and 17‑fold vs newborn controls) and non‑overlapping with controls; this supports potential screening workflows (including newborn screening concepts), while emphasizing that genetic testing is still required for subtype assignment and that MLIIIγ stratification was limited by small sample size (n=1 MLIIIγ). (hong2023multiplextandemmass pages 2-4)

10.4 Differential diagnosis

MLII/III shares clinical overlap with mucopolysaccharidoses (MPS) (skeletal dysplasia/dysostosis multiplex), and biochemical enzyme panels alone cannot subtype; confirmation requires GNPTAB/GNPTG sequencing. (khan2020mucolipidosesoverviewpast pages 3-6)

11. Outcome / prognosis

A systematic review of 843 published MLII/III cases reported for MLIII (all subtypes): median survival 62.0 years and median age of death 33.0 years (not GNPTG‑specific, but MLIIIγ is described as the least severe ML phenotype). (dogterom2021mucolipidosistypeii pages 1-2)

12. Treatment

12.1 Current standard of care and real‑world implementations

No definitive disease‑modifying therapy was identified in the retrieved evidence; sources emphasize that treatment is largely supportive/symptomatic, with orthopedic management addressing joint disease (e.g., joint replacement in severe hip disease). (khan2020mucolipidosesoverviewpast pages 1-3, geer2023unravelingmucolipidosistype pages 1-2)

12.2 Clinical trials / advanced therapeutics

No GNPTG/MLIIIγ‑specific clinical trials or NCT identifiers were retrieved in this run.

12.3 Suggested MAXO terms (conceptual)

Supportive care; orthopedic surgery; physical therapy/rehabilitation; genetic counseling.

13. Prevention

Primary prevention is not applicable in the usual public‑health sense for a Mendelian disorder; prevention focuses on genetic counseling, carrier testing, and prenatal/preimplantation options, but these were not detailed in the retrieved evidence.

14. Other species / natural disease

No naturally occurring non‑human GNPTG‑mucolipidosis cases were identified in the retrieved evidence.

15. Model organisms

A Gnptg knockout mouse has been used as an MLIIIγ model. The study linked lysosomal enzyme missorting to cartilage homeostasis failure and joint dysfunction, including chondroitin sulfate accumulation in chondrocytes and altered ECM structure, with functional joint abnormalities and impaired motor performance under fatigue/pain conditions. (westermann2020imbalancedcellularmetabolism pages 42-44)

Visual evidence (phenotype)

A joint‑mobility figure illustrating range‑of‑motion abnormalities across MLII/MLIII subtypes (including MLIIIγ) was retrieved from the Gnptg mouse/human comparative study. (westermann2020imbalancedcellularmetabolism media df302704)

Evidence table (structured summary)

Category Key facts Key sources (with PMID if known; otherwise DOI/URL) Publication year
Disease entity / synonyms GNPTG-associated disease is mucolipidosis type III gamma (MLIIIγ), an attenuated lysosomal storage disorder within the MLII/III spectrum; historical synonym pseudo-Hurler polydystrophy is used in MLIII literature. All pathogenic GNPTG variants reported in the systematic review resulted in the MLIII gamma phenotype. (velho2019thelysosomalstorage pages 1-3, persichetti2009identificationandmolecular pages 1-2, dogterom2021mucolipidosistypeii pages 1-2) Velho et al., Hum Mutat 2019, DOI: https://doi.org/10.1002/humu.23748; Persichetti et al., Hum Mutat 2009, DOI: https://doi.org/10.1002/humu.20959; Dogterom et al., Genet Med 2021, DOI: https://doi.org/10.1038/s41436-021-01244-4 2009, 2019, 2021
Causal gene Causal gene: GNPTG, encoding the soluble γ-subunit of N-acetylglucosamine-1-phosphotransferase (GlcNAc-1-phosphotransferase), part of the α2β2γ2 hexameric complex. (velho2019thelysosomalstorage pages 1-3, sohn2016moleculargeneticsand pages 1-2, dogterom2021mucolipidosistypeii pages 1-2, khan2020mucolipidosesoverviewpast pages 3-6) Velho et al., DOI: https://doi.org/10.1002/humu.23748; Sohn, DOI: https://doi.org/10.19125/jmrd.2016.2.1.13; Dogterom et al., DOI: https://doi.org/10.1038/s41436-021-01244-4 2016, 2019, 2021
Inheritance Autosomal recessive inheritance. MLIIIγ is consistently described as the mildest/least severe GlcNAc-1-phosphotransferase–related mucolipidosis phenotype. (velho2019thelysosomalstorage pages 1-3, sohn2016moleculargeneticsand pages 1-2, meel2016mucolipidosisiiignptg pages 1-3, hong2023multiplextandemmass pages 1-2) Velho et al., DOI: https://doi.org/10.1002/humu.23748; Sohn, DOI: https://doi.org/10.19125/jmrd.2016.2.1.13; van Meel & Kornfeld, DOI: https://doi.org/10.1002/humu.22993; Hong et al., DOI: https://doi.org/10.1016/j.ymgmr.2023.100978 2016, 2019, 2023
Key mechanism / pathophysiology GlcNAc-1-phosphotransferase catalyzes the first step of mannose-6-phosphate (M6P) tagging of lysosomal hydrolases. GNPTG deficiency reduces phosphorylation of a subset of lysosomal enzymes, causing missorting into the extracellular space, lysosomal enzyme shortage within lysosomes, and accumulation of undegraded substrates in enlarged lysosomes. (velho2019thelysosomalstorage pages 1-3, meel2016mucolipidosisiiignptg pages 1-3, khan2020mucolipidosesoverviewpast pages 1-3, dogterom2021mucolipidosistypeii pages 1-2, khan2020mucolipidosesoverviewpast pages 3-6) Velho et al., DOI: https://doi.org/10.1002/humu.23748; van Meel & Kornfeld, DOI: https://doi.org/10.1002/humu.22993; Khan & Tomatsu, DOI: https://doi.org/10.3390/ijms21186812; Dogterom et al., DOI: https://doi.org/10.1038/s41436-021-01244-4 2016, 2019, 2020, 2021
Variant classes / molecular effects Reported pathogenic GNPTG variants include missense, nonsense, splice-site, and frameshift/microdeletion alleles. Missense variants such as p.G106S, p.G126S, p.C142Y can cause misfolding, ER retention, and aggregation; other alleles produce aberrant splicing or nonsense-mediated decay. (persichetti2009identificationandmolecular pages 1-2, meel2016mucolipidosisiiignptg pages 1-3) Persichetti et al., DOI: https://doi.org/10.1002/humu.20959; van Meel & Kornfeld, DOI: https://doi.org/10.1002/humu.22993 2009, 2016
Hallmark biochemical findings Diagnostic hallmark: elevated lysosomal enzyme activities in plasma/serum due to hypersecretion, with relatively decreased or low-normal leukocyte/fibroblast activities; urinary GAGs are often normal in MLII/III while oligosaccharides may be increased. (sohn2016moleculargeneticsand pages 1-2, meel2016mucolipidosisiiignptg pages 1-3, khan2020mucolipidosesoverviewpast pages 3-6, geer2023unravelingmucolipidosistype pages 2-5, geer2023unravelingmucolipidosistype pages 1-2) Sohn, DOI: https://doi.org/10.19125/jmrd.2016.2.1.13; van Meel & Kornfeld, DOI: https://doi.org/10.1002/humu.22993; Khan & Tomatsu, DOI: https://doi.org/10.3390/ijms21186812; De Geer et al., DOI: https://doi.org/10.1186/s12886-023-03136-4 2016, 2020, 2023
Quantitative biochemical examples In the 2023 GNPTG case with retinitis pigmentosa, plasma enzymes were markedly elevated, e.g. β-glucuronidase 1370 µkat/L vs 42 control, Hexosaminidase B 5190 vs 135, β-galactosidase 4.2 vs 0.9; leukocyte activities were slightly decreased or low-normal. (geer2023unravelingmucolipidosistype pages 2-5) De Geer et al., BMC Ophthalmol 2023, DOI: https://doi.org/10.1186/s12886-023-03136-4 2023
Core clinical features Typical MLIIIγ features include joint stiffness/restricted mobility, claw-hand deformity, short stature, scoliosis, progressive bone/joint disease, hip destruction/replacement, carpal/tarsal tunnel syndrome, and valvular heart disease; intellect is often normal or only mildly affected. (persichetti2009identificationandmolecular pages 1-2, meel2016mucolipidosisiiignptg pages 1-3, dogterom2021mucolipidosistypeii pages 1-2, geer2023unravelingmucolipidosistype pages 1-2, westermann2020imbalancedcellularmetabolism media df302704) Persichetti et al., DOI: https://doi.org/10.1002/humu.20959; van Meel & Kornfeld, DOI: https://doi.org/10.1002/humu.22993; Dogterom et al., DOI: https://doi.org/10.1038/s41436-021-01244-4; De Geer et al., DOI: https://doi.org/10.1186/s12886-023-03136-4 2009, 2016, 2021, 2023
Tissue/anatomic emphasis Human and mouse data support major involvement of connective tissue, cartilage, tendon, bone, and joints; Gnptg knockout studies link enzyme missorting to chondroitin sulfate accumulation in chondrocytes, altered ECM structure, and functional joint abnormalities. (westermann2020imbalancedcellularmetabolism pages 42-44, westermann2020imbalancedcellularmetabolism media df302704) Westermann et al., Dis Model Mech 2020, DOI: https://doi.org/10.1242/dmm.046425 2020
Natural history / prognosis MLIII is later-onset and longer-surviving than MLII. Systematic review statistics: median age at diagnosis 9.0 years for MLIII; median survival 62.0 years; median age at death 33.0 years in reported cases. (dogterom2021mucolipidosistypeii pages 1-2) Dogterom et al., DOI: https://doi.org/10.1038/s41436-021-01244-4 2021
Epidemiology Reported combined prevalence for MLII/III is approximately 0.22–2.70 per 100,000 live births; GNPTG-specific prevalence was not separately quantified in the provided evidence. (hong2023multiplextandemmass pages 1-2) Hong et al., DOI: https://doi.org/10.1016/j.ymgmr.2023.100978 2023
Recent development: multiplex DBS MS/MS assay 2023: multiplex UPLC-MS/MS dried blood spot assay measured 12 lysosomal enzymes in MLII/III and showed a characteristic pattern, supporting screening/diagnosis and potential newborn screening workflows. In DBS, ASM, IDS, and NAGLU were significantly elevated; in the cohort these were about 20-fold, 11-fold, and 17-fold above newborn controls, respectively. Molecular testing is still needed to distinguish MLIIIγ from other MLII/III subtypes. (hong2023multiplextandemmass pages 1-2, hong2023multiplextandemmass pages 2-4) Hong et al., Mol Genet Metab Rep 2023, DOI: https://doi.org/10.1016/j.ymgmr.2023.100978 2023
Recent development: WGS phenotype expansion 2023: whole genome sequencing in a 47-year-old patient with late-onset retinal disease identified compound heterozygous GNPTG variants c.347_349del (p.Asn116del) and c.607dup (p.Gln203fs), leading to diagnosis of MLIIIγ. This was reported as the first description of retinitis pigmentosa/late-onset retinal dystrophy in GNPTG-related MLIIIγ, expanding the phenotype. (geer2023unravelingmucolipidosistype pages 2-5, geer2023unravelingmucolipidosistype pages 1-2) De Geer et al., BMC Ophthalmol 2023, DOI: https://doi.org/10.1186/s12886-023-03136-4 2023
Current diagnostic approach Best-supported approach combines clinical suspicion, biochemical evidence of hypersecreted lysosomal enzymes (plasma/serum ± DBS), and molecular confirmation by GNPTG sequencing; biochemical testing alone cannot reliably subtype MLII vs MLIIIα/β vs MLIIIγ. (sohn2016moleculargeneticsand pages 1-2, khan2020mucolipidosesoverviewpast pages 3-6, hong2023multiplextandemmass pages 2-4) Sohn, DOI: https://doi.org/10.19125/jmrd.2016.2.1.13; Khan & Tomatsu, DOI: https://doi.org/10.3390/ijms21186812; Hong et al., DOI: https://doi.org/10.1016/j.ymgmr.2023.100978 2016, 2020, 2023
Treatment status No curative or disease-modifying therapy was identified in the provided GNPTG-focused evidence; management remains largely supportive/symptomatic, and curative treatment was noted as unavailable in reviews/systematic summaries. (sohn2016moleculargeneticsand pages 1-2, khan2020mucolipidosesoverviewpast pages 1-3, dogterom2021mucolipidosistypeii pages 1-2) Sohn, DOI: https://doi.org/10.19125/jmrd.2016.2.1.13; Khan & Tomatsu, DOI: https://doi.org/10.3390/ijms21186812; Dogterom et al., DOI: https://doi.org/10.1038/s41436-021-01244-4 2016, 2020, 2021

Table: This table condenses the core disease-defining facts for GNPTG-associated mucolipidosis type III gamma, including mechanism, clinical and biochemical hallmarks, natural history, and the most relevant 2023 diagnostic/phenotypic updates.

Expert synthesis / analysis (grounded in cited sources)

1) The convergent biochemical hallmark—high plasma lysosomal enzymes—is mechanistically coherent with M6P tagging failure and provides a high‑yield diagnostic clue, but molecular confirmation is required for subtype assignment and genetic counseling. (dogterom2021mucolipidosistypeii pages 1-2, hong2023multiplextandemmass pages 2-4) 2) 2023 data suggest practical pathways for earlier detection: DBS‑based MS/MS assays can provide a scalable biochemical screen, whereas WGS can resolve atypical phenotypes and broaden disease recognition (e.g., retinal dystrophy). Together, these support a “biochemical screen → genomic confirmation” diagnostic paradigm for MLII/III. (hong2023multiplextandemmass pages 2-4, geer2023unravelingmucolipidosistype pages 1-2)

Notes on evidence limits and gaps

  • Identifiers (OMIM/Orphanet/ICD/MeSH/MONDO), carrier frequencies/gnomAD allele frequencies, and formal clinical guidelines were not present in the retrieved full‑text evidence, so they are intentionally not populated here.
  • A 2024 mucolipidosis review was retrieved but primarily provides a broad overview; detailed GNPTG‑specific treatment innovations in 2024 were not available in the accessible evidence set. (westermann2020imbalancedcellularmetabolism media df302704)

References

  1. (velho2019thelysosomalstorage pages 1-3): Renata Voltolini Velho, Frederike L. Harms, Tatyana Danyukova, Nataniel F. Ludwig, Michael J. Friez, Sara S. Cathey, Mirella Filocamo, Barbara Tappino, Nilay Güneş, Beyhan Tüysüz, Karen L. Tylee, Kathryn L. Brammeier, Lesley Heptinstall, Esmee Oussoren, Ans T. Ploeg, Christine Petersen, Sandra Alves, Gloria Durán Saavedra, Ida V. Schwartz, Nicole Muschol, Kerstin Kutsche, and Sandra Pohl. The lysosomal storage disorders mucolipidosis type ii, type iii alpha/beta, and type iii gamma: update on gnptab and gnptg mutations. Human Mutation, 40:842-864, Jul 2019. URL: https://doi.org/10.1002/humu.23748, doi:10.1002/humu.23748. This article has 81 citations and is from a domain leading peer-reviewed journal.

  2. (dogterom2021mucolipidosistypeii pages 1-2): Emma J. Dogterom, Margreet A.E.M. Wagenmakers, Martina Wilke, Serwet Demirdas, Nicole M. Muschol, Sandra Pohl, Jan C. van der Meijden, Dimitris Rizopoulos, Ans T. van der Ploeg, and Esmée Oussoren. Mucolipidosis type ii and type iii: a systematic review of 843 published cases. Genetics in Medicine, 23:2047-2056, Nov 2021. URL: https://doi.org/10.1038/s41436-021-01244-4, doi:10.1038/s41436-021-01244-4. This article has 44 citations and is from a highest quality peer-reviewed journal.

  3. (hong2023multiplextandemmass pages 1-2): Xinying Hong, Laura Pollard, Miao He, Michael H. Gelb, and Timothy C. Wood. Multiplex tandem mass spectrometry enzymatic activity assay for the screening and diagnosis of mucolipidosis type ii and iii. Jun 2023. URL: https://doi.org/10.1016/j.ymgmr.2023.100978, doi:10.1016/j.ymgmr.2023.100978. This article has 6 citations.

  4. (geer2023unravelingmucolipidosistype pages 2-5): Karl De Geer, Katarzyna Mascianica, Karin Naess, Eliane Sardh, Anna Lindstrand, and Erik Björck. Unraveling mucolipidosis type iii gamma through whole genome sequencing in late-onset retinitis pigmentosa: a case report. BMC Ophthalmology, Sep 2023. URL: https://doi.org/10.1186/s12886-023-03136-4, doi:10.1186/s12886-023-03136-4. This article has 5 citations and is from a peer-reviewed journal.

  5. (persichetti2009identificationandmolecular pages 1-2): Emanuele Persichetti, Nadia A. Chuzhanova, Andrea Dardis, Barbara Tappino, Sandra Pohl, Nick S.T. Thomas, Camillo Rosano, Chiara Balducci, Silvia Paciotti, Silvia Dominissini, Anna Lisa Montalvo, Michela Sibilio, Rossella Parini, Miriam Rigoldi, Maja Di Rocco, Giancarlo Parenti, Aldo Orlacchio, Bruno Bembi, David N. Cooper, Mirella Filocamo, and Tommaso Beccari. Identification and molecular characterization of six novel mutations in the udp‐n‐acetylglucosamine‐1‐phosphotransferase gamma subunit (gnptg) gene in patients with mucolipidosis iii gamma. Human Mutation, 30:978-984, Jun 2009. URL: https://doi.org/10.1002/humu.20959, doi:10.1002/humu.20959. This article has 44 citations and is from a domain leading peer-reviewed journal.

  6. (geer2023unravelingmucolipidosistype pages 1-2): Karl De Geer, Katarzyna Mascianica, Karin Naess, Eliane Sardh, Anna Lindstrand, and Erik Björck. Unraveling mucolipidosis type iii gamma through whole genome sequencing in late-onset retinitis pigmentosa: a case report. BMC Ophthalmology, Sep 2023. URL: https://doi.org/10.1186/s12886-023-03136-4, doi:10.1186/s12886-023-03136-4. This article has 5 citations and is from a peer-reviewed journal.

  7. (westermann2020imbalancedcellularmetabolism pages 42-44): Lena Marie Westermann, Lutz Fleischhauer, Jonas Vogel, Zsuzsa Jenei-Lanzl, Nataniel Floriano Ludwig, Lynn Schau, Fabio Morellini, Anke Baranowsky, Timur A. Yorgan, Giorgia Di Lorenzo, Michaela Schweizer, Bruna de Souza Pinheiro, Nicole Ruas Guarany, Fernanda Sperb-Ludwig, Fernanda Visioli, Thiago Oliveira Silva, Jamie Soul, Gretl Hendrickx, J. Simon Wiegert, Ida V. D. Schwartz, Hauke Clausen-Schaumann, Frank Zaucke, Thorsten Schinke, Sandra Pohl, and Tatyana Danyukova. Imbalanced cellular metabolism compromises cartilage homeostasis and joint function in a mouse model of mucolipidosis type iii gamma. Disease Models & Mechanisms, Nov 2020. URL: https://doi.org/10.1242/dmm.046425, doi:10.1242/dmm.046425. This article has 10 citations and is from a domain leading peer-reviewed journal.

  8. (khan2020mucolipidosesoverviewpast pages 3-6): Shaukat A. Khan and Saori C. Tomatsu. Mucolipidoses overview: past, present, and future. International Journal of Molecular Sciences, 21:6812, Sep 2020. URL: https://doi.org/10.3390/ijms21186812, doi:10.3390/ijms21186812. This article has 78 citations.

  9. (meel2016mucolipidosisiiignptg pages 1-3): Eline van Meel and Stuart Kornfeld. Mucolipidosis iii gnptg missense mutations cause misfolding of the γ subunit of glcnac‐1‐phosphotransferase. Human Mutation, 37:623-626, Jul 2016. URL: https://doi.org/10.1002/humu.22993, doi:10.1002/humu.22993. This article has 4 citations and is from a domain leading peer-reviewed journal.

  10. (sohn2016moleculargeneticsand pages 1-2): Young Bae Sohn. Molecular genetics and diagnostic approach of mucolipidosis ii/iii. ArXiv, 2:13-16, Jun 2016. URL: https://doi.org/10.19125/jmrd.2016.2.1.13, doi:10.19125/jmrd.2016.2.1.13. This article has 0 citations.

  11. (hong2023multiplextandemmass pages 2-4): Xinying Hong, Laura Pollard, Miao He, Michael H. Gelb, and Timothy C. Wood. Multiplex tandem mass spectrometry enzymatic activity assay for the screening and diagnosis of mucolipidosis type ii and iii. Jun 2023. URL: https://doi.org/10.1016/j.ymgmr.2023.100978, doi:10.1016/j.ymgmr.2023.100978. This article has 6 citations.

  12. (khan2020mucolipidosesoverviewpast pages 1-3): Shaukat A. Khan and Saori C. Tomatsu. Mucolipidoses overview: past, present, and future. International Journal of Molecular Sciences, 21:6812, Sep 2020. URL: https://doi.org/10.3390/ijms21186812, doi:10.3390/ijms21186812. This article has 78 citations.

  13. (westermann2020imbalancedcellularmetabolism media df302704): Lena Marie Westermann, Lutz Fleischhauer, Jonas Vogel, Zsuzsa Jenei-Lanzl, Nataniel Floriano Ludwig, Lynn Schau, Fabio Morellini, Anke Baranowsky, Timur A. Yorgan, Giorgia Di Lorenzo, Michaela Schweizer, Bruna de Souza Pinheiro, Nicole Ruas Guarany, Fernanda Sperb-Ludwig, Fernanda Visioli, Thiago Oliveira Silva, Jamie Soul, Gretl Hendrickx, J. Simon Wiegert, Ida V. D. Schwartz, Hauke Clausen-Schaumann, Frank Zaucke, Thorsten Schinke, Sandra Pohl, and Tatyana Danyukova. Imbalanced cellular metabolism compromises cartilage homeostasis and joint function in a mouse model of mucolipidosis type iii gamma. Disease Models & Mechanisms, Nov 2020. URL: https://doi.org/10.1242/dmm.046425, doi:10.1242/dmm.046425. This article has 10 citations and is from a domain leading peer-reviewed journal.

Artifacts